Malignant Neoplasms of Female Genital Organs Clinical Trial
Official title:
A Single Center, Prospective, Randomized, Controlled Study to Evaluate Shoulder Pain, Cardiovascular Changes, Pulmonary Pressures and Perioperative Outcomes Related to the Use of the AirSeal® Insufflation System (AIS) at Low and Higher Pressure Pneumoperitoneum vs. Conventional Insufflation
Verified date | May 2019 |
Source | M.D. Anderson Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this clinical research study is to compare the level of pain 2 hours after surgery in patients after the use of the AirSeal® Insufflation System (AIS) at a high or low pressure setting or the standard insufflator (the conventional insufflation system, or CIS). "Insufflation" is the creation of a pressure barrier of air/gas within the abdomen that allows the surgeon more space to work in.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | July 2022 |
Est. primary completion date | July 2021 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: 1. All gynecologic laparoscopic/robotic surgeries EXCEPT diagnostic laparoscopies 2. 18-80 years of age 3. Capable and willing to provide Informed consent 4. Acceptable candidate for laparoscopic/robotic GYN surgery as per discretion of the surgeon 5. If patient agrees to participate in the optional patient reported outcomes portion of the study, patient must be English speaking and willing to complete the MD Anderson Symptom Inventory (MDASI) questionnaires Exclusion Criteria: 1. Active cutaneous infection or inflammation 2. Pre-existing active or untreated immunodeficiency disorder and/or chronic use of systemic steroids 3. Uncontrolled diabetes mellitus 4. Severe co-existing morbidities having a life expectancy of less than 30 days 5. Significant anemia with hemoglobin level less than 7 g/dL or a hematocrit less than 21% 6. Females who are pregnant or lactating 7. Patients presenting with ascites 8. Patients with Chronic Pain Syndrome or requiring/using chronic pain medications 9. Patients undergoing diagnostic laparoscopy 10. Patients planning to undergo hand-assisted laparoscopy 11. Severe comorbidities (atrial fibrillation, pulmonary hypertension, etc...) |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
M.D. Anderson Cancer Center | ConMed Corporation |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of Shoulder Pain After Laparoscopic/Robotic Surgery | Incidence of shoulder pain defined by a positive (>0) score for an 11-point pain intensity numeric rating scale (PI-NRS). | Post-operative day 1 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02812056 -
Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT02714439 -
Low-Cost Imaging for Cervical Cancer Prevention in the Texas Lower Rio Grande Valley
|
Early Phase 1 | |
Active, not recruiting |
NCT02774759 -
Feasibility of the NEXT Steps Weight Loss Intervention +/- Resistance Training for Endometrial Cancer Survivors: Effect on Lean Mass & Biomarkers
|
N/A | |
Recruiting |
NCT03093909 -
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
|
Phase 1 | |
Completed |
NCT03210376 -
Neuromuscular Blockade on Shoulder Pain of Elderly
|
Phase 4 | |
Recruiting |
NCT02884648 -
Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery
|
Phase 2 | |
Active, not recruiting |
NCT03435952 -
Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
|
Phase 1 | |
Withdrawn |
NCT02915172 -
Lenvatinib and Capecitabine in Patients With Advanced Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT03162627 -
Selumetinib and Olaparib in Solid Tumors
|
Phase 1 | |
Terminated |
NCT02740114 -
Wound Infiltration With Liposomal Bupivacaine vs. Standard Wound Infiltration With Bupivacaine in Patient's Undergoing Open Gynecologic Surgery on an Enhanced Recovery Pathway
|
Phase 3 | |
Active, not recruiting |
NCT03531645 -
Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma
|
Phase 2 |